Abstract
Importance Impaired cognitive function is a hallmark of neuropsychiatric disease, posing a significant challenge to patients, clinicians and healthcare systems. Emerging research on ketone bodies suggests they may function as an alternative fuel for the brain, potentially enhancing cognitive function through both metabolic and signaling pathways. An alternative to inducing ketosis by lowering dietary carbohydrate intake is consumption of exogenous ketones (EK).
Objective It is unknown whether the existing literature collectively supports a beneficial effect of EK on cognitive function; this systematic review and metanalysis aims to aggregate available data and address this gap.
Data Sources PubMed, Web of Science, and EMBASE databases were searched in October 2023 for key words and free words referring to ketone bodies, cognition, and health-related conditions.
Study Selection Multiple reviewers selected 29 studies for inclusion in the analysis from the initial 1678 search results, which included randomized control studies of healthy participants and patients with neuropsychiatric conditions, using exogenous ketones as an intervention alongside a placebo, that included outcomes assessing cognitive function.
Data Extraction and Synthesis A PRISMA model was used for abstracting data, and the PEDRo scale was used to assess study quality. Data was extracted and verified by independent investigators.
Main Outcome Cognitive function measures.
Results 29 studies (1,347 participants) were included, with 18 studies (875 participants) in the meta-analysis. Results indicate that EK administration has a modest but statistically significant positive effect on cognitive performance (SMD = 0.26, 95% CI: 0.11 – 0.40, p = 0.0007). Sub-group analyses showed no significant differences between study duration (acute vs. intermediate; p = 0.50), ketone form (mono-esters vs. medium-chain triglycerides; p = 0.06), population type (healthy vs. Alzheimer’s disease; p = 0.21), or the presence of acute cognitive stressors (p = 0. 25).
Conclusions The findings suggest that EK could be a promising adjunctive strategy in dementia management, offering potential benefits even in patients who maintain sufficient carbohydrate intake. EK may provide psychiatrists with an innovative, non-invasive approach to supporting cognitive resilience in patients with neuropsychiatric disorders. Further clinical trials should refine the therapeutic application of EK and integrate them into comprehensive neuropsychiatric care protocols.
Key points Question: Does the consumption of exogenous ketones improve cognitive function, and what are the variables that influence efficacy.
Finding: Exogenous ketones have a modest but significant effect on overall cognitive performance outcomes, with no clear effect of study duration or population, ketone form or dose, or the presence of a stressor.
Meaning: These findings strongly support further research to determine the ideal administration strategy for exogenous ketones to improve cognitive function.
Competing Interest Statement
BJS. has an equity interest in HVMN Inc., and stock options in BHB Therapeutics Ltd who both market products related to ketone bodies. BJS. is an inventor on patents related to the use of ketone bodies assigned to The Buck Institute for Research on Aging. MD and ACB were employed by Component Health Ltd, who commercialize ketone ester product, at the time the work was carried out. All other authors have no disclosures
Funding Statement
BJS was supported by the NIA under award number K01AG078125.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: BJS was supported by the NIA under award number K01AG078125.
Disclosure: BJS. has an equity interest in HVMN Inc., and stock options in BHB Therapeutics Ltd who both market products related to ketone bodies. BJS. is an inventor on patents related to the use of ketone bodies assigned to The Buck Institute for Research on Aging. MD and ACB were employed by Component Health Ltd, who commercialize ketone ester product, at the time the work was carried out. All other authors have no disclosures.
Acknowledgements: The authors thank Dr Barbara Sahakian for her thoughtful comments on this manuscript
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- AcAc
- Acetoacetate
- AD
- Alzheimer’s Disease
- ADAS-Cog
- Alzheimer’s Disease Assessment Scale-Cognitive Subscale
- ADRD
- Alzheimer’s Disease and Related Dementias
- BHB
- D-β-hydroxybutyrate
- EK
- Exogenous ketones
- kMCT
- Ketogenic MCT
- KME
- Ketone monoester
- MCI
- Mild cognitive impairment
- MCT
- Medium chain triglyceride
- mM
- millimolar
- MMSE
- Mini mental state examination
- PRISMA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- SD
- Standard deviation of the mean
